Welcome to our dedicated page for Seres Therapeutics news (Ticker: MCRB), a resource for investors and traders seeking the latest updates and insights on Seres Therapeutics stock.
Seres Therapeutics, Inc. develops live biotherapeutic products and microbiome-based therapies for inflammatory, immune, infectious and gastrointestinal diseases. Company updates commonly address pipeline programs such as SER-155 for immune checkpoint inhibitor-related enterocolitis and prevention of bloodstream infections in allogeneic hematopoietic stem cell transplant patients, SER-603 for inflammatory bowel disease, and SER-428 for antimicrobial resistance and serious infections.
Recurring announcements include financial results, operational updates, research publications, scientific conference presentations, biomarker and microbiome-mechanism data, collaborations, financing and partnership activity, cost-control measures, and governance changes.
Seres Therapeutics (Nasdaq:MCRB) reported second quarter 2026 net income of $4.6 million, versus a $19.9 million loss a year earlier, mainly driven by a $25 million gain on sale of the VOWST business tied to a milestone termination payment from Nestlé Health Science.
R&D expenses fell to $9.1 million and G&A to $7.1 million, partly offset by a $5.8 million lease impairment. Seres announced early termination of its 200 Sidney Street lease and a previously restructured 101 CambridgePark Drive lease, which are expected to materially reduce future facility cash costs and lease obligations.
Clinically, an MSK investigator-sponsored trial of SER-155 in immune checkpoint inhibitor-related enterocolitis showed 80% of 15 participants achieved immunosuppressive-free clinical response at day 15, with no safety concerns identified. Cash and equivalents were $15.6 million on June 30, 2026, and the company expects its cash, including Nestlé payments, to fund operations into the first quarter of 2027.
Seres Therapeutics (Nasdaq:MCRB) reported early clinical data from a 15-patient MSK investigator-sponsored trial of SER-155 in immune checkpoint inhibitor-related enterocolitis (irEC).
At Day 15, 80% achieved immunosuppressive-free clinical response and 33% complete remission; SER-155 was generally well tolerated and showed biomarker and microbiome engraftment changes supporting further development.
Seres Therapeutics (Nasdaq:MCRB) will host a webcast on July 8, 2026, at 8:30 a.m. ET to discuss top-line results from an investigator-sponsored trial of SER-155 in immune checkpoint inhibitor-related enterocolitis.
The event will be accessible via conference call and live webcast with replay available.
Seres Therapeutics (Nasdaq:MCRB) announced two transactions to bolster liquidity and cut facility costs. Nestlé Health Science will pay $25 million in 2026 to buy out future VOWST net sales milestones, and a restructured lease is expected to materially lower annual facility cash spending and long-term obligations.
With $29.8 million in cash as of March 31, 2026, Seres now expects its operating cash runway to extend well into Q1 2027 and anticipates SER-155 clinical data in immune checkpoint inhibitor-related enterocolitis later this month.
Seres Therapeutics (Nasdaq:MCRB) announced that management will present a company overview at the H.C. Wainwright 4th Annual BioConnect Investor Conference at 3:30 p.m. ET on May 19, 2026.
A live webcast and replay will be available via the company’s investor relations website.
Seres (Nasdaq: MCRB) reported Q1 2026 results and business updates on May 5, 2026. Key items: investigator-sponsored SER-155 irEC study readout expected in the coming weeks (15 patients enrolled), SER-155 Phase 2 readiness for allo-HSCT, IND-enabling work for SER-603, CARB-X–supported SER-428 development, and $29.8M cash expected to fund operations through Q3 2026.
Q1 2026 net loss was $19.9M versus net income of $32.7M in Q1 2025; R&D was $13.2M and G&A was $8.1M.
Seres Therapeutics (Nasdaq: MCRB) presented preclinical data at Digestive Disease Week 2026 supporting SER-603, a next-generation cultivated live biotherapeutic candidate for inflammatory bowel disease (IBD). The poster was selected as a DDW Poster of Distinction and highlights rational strain selection, biomarker-driven patient stratification, and IND-enabling progress.
Data show SER-603 reduced inflammatory cytokine production in a MiGUT in vitro gut model and the company reports engagement with potential collaborators to support clinical development.
Seres Therapeutics (Nasdaq: MCRB) presented Phase 1b and translational data at ESCMID Global 2026 (April 17–21). Seres reported that SER-155 induced a significant, durable shift in GI microbiome composition and was associated with improved GI epithelial barrier integrity versus placebo.
Presentations included a SER-155 poster, an oral MiGut model talk with University of Leeds collaboration, and a symposium on microbiome strategies in immunocompromised patients.
Seres Therapeutics (Nasdaq: MCRB) will present at the CARB-X Investor Day on April 16, 2026, ahead of ESCMID in Munich. Elizabeth Halvorsen, Ph.D., will overview Seres’ therapeutic platform and its CARB-X collaboration. In 2025 Seres received up to $3.6 million from CARB-X to advance SER-428, an oral liquid formulation derived from SER-155 strains, and is designing a Phase 1b open-label trial in medical ICU patients.
Seres Therapeutics (Nasdaq: MCRB) reported fourth-quarter and full-year 2025 results and business updates on March 12, 2026. Key points: clinical data from a 15-subject investigator-sponsored SER-155 study in immune checkpoint–related enterocolitis is expected in Q2 2026, SER-603 IND-enabling work continues, and the company had $45.8M cash at year-end with runway into Q3 2026.
Full-year net income from continuing operations was $5.7M, driven by lower operating expenses and installment payments from Nestle.